January 2019: Held Hrain Phase I Clinical Trial Kick-off Meeting for anti-human CD19 T cell injection(against R/R Acute Lymphocytic Leukemia);
January 2018: The first success of CAR-T infusion by Hrain in a patient with liver cancer;
January 2018: 93 of the 130 enrolled patients received infusion.
January 2018: Started cooperation with Zhongshan Hospital affiliated to Fudan University and became the first clinical trial center of Hrain for registered clinical research projects;
February 2018: Submitted to NMPA the application of Phase I clinical trial registration for acute lymphoblastic leukemia;
March 2018: Completed A round financing;
April 2018: Started the construction of the Cell Processing Center;
May 2018: Submitted to NMPA the application of Phase I clinical trial registration for multiple myeloma;
July 2018: Completed A+ round financing;
July 2018: Two anti-human CD19 T cell injections were approved by NMPA for clinical trials;
July 2018: Won the 2018 Frost & Sullivan's China New Economy Award — Excellence in Innovation;
August 2018: Started the collaboration with Shanghai First People's Hospital affiliated to Shanghai Jiaotong University and had the 13th clinical cooperation centers;
September 2018: Officially launched Shanghai Zhangjiang Jinshan Biological Base;
October 2018: Held Hrain Phase I Clinical Trial Kick-off Meeting for anti-human CD19 T cell injection(against r/r Lymphoma);
October 2018: Vice President of Hrain hosted the 2018 Advanced Cell Therapy Shanghai Summit;
November 2018: Hrain products were included into the biomedical exhibition area of Zhangjiang Science City (inspected by General Secretary Xi Jinping)
November 2018: Successfully held the 13th Annual Meeting of Chinese Society for Immunology - Hrain Satellite Conference
December 2018: Anti-human BCMA T cell injection was approved for clinical use
January 2017: The first success of CAR-T infusion by Hrain in a patient with multiple myeloma;
February 2017: Launched the expansion of the platform to 3,000 square meters;
November 2017: Submitted to Shanghai Food and Drug Administration the application of Phase I clinical trial registration for lymphoma;
December 2017: Started the cooperation with Shanghai Changzheng Hospital and had the 11st clinical cooperation centers.
February 2016: Registered another 2 clinical trials on ClinicalTrials.gov, reaching 8 in total;
February 2016: The first success of CAR-T infusion by Hrain in a patient with leukemia.
April 2015: Completed the construction of the technology platform in Zhangjiang;
July 2015: Hrain Biotechnology founded;
September 2015: Held the CAR-T Clinical Trial Kick-off Meeting;
September 2015: Started the cooperation with Chongqing Xinqiao Hospital -- the first CAR-T clinical cooperation center;
October 2015: Realized stable production of virus-based CAR-Ts;
December 2015: The first success of CAR-T infusion by Hrain in a patient with B-cell lymphoma.